// App-Quantinova.ai

P758 : INHIBITION OF ATR WITH CERALASERTIB (AZD6738) FOR THE TREATMENT OF PROGRESSIVE OR RELAPSED MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A PHASE IB/II STUDY

Researchers

Presenter

  • Andrew Brunner

Principal Investigators

  • Yiwen Liu

  • Jacqueline Garcia

  • Philip Amrein

  • Donna Neuberg

  • Emma Dean

  • Simon Smith

  • Richard Stone

  • Amir Fathi

  • Meagan Jacoby

Medical Centers

  • Dana-Farber Cancer Institute Boston,Boston,Stati Uniti

  • Washin

  • Dana-Faber Cancer Institute,Boston,Verenigde Staten

  • Washington University School of Medicine, St. Louis, MO

  • AstraZeneca,Cambridge,Reino Unido

  • Dana-Farber Cancer Institute Boston,Boston,Stati Uniti

  • Dana-Farber Cancer Institute, Boston, MA, United States

  • Dana-Faber Cancer Institute,Boston,Verenigde Staten

  • Beth Israel Deaconess Medical Center,Boston,États-unis

  • Massachusetts General Hospital,Boston, MA,Stati Uniti

  • Beth-Israel Deaconess Medical Center,Boston,United States

  • Dana-Farber Cancer Institute, Boston, MA

  • Massachusetts General Hospital, Boston, MA, United States

  • Massachusetts General Hospital,Boston,Vereinigte Staaten

  • AstraZeneca,Cambridge,Verenigd Koninkrijk

  • Beth-Israel Deaconess Medical Center,Boston,United States

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Beth-Israel Deaconess Medical Center,Boston,United States

  • Massachusetts General Hospital,Boston, MA,Stati Uniti

  • Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, United States

  • Beth Israel Deaconess Medical Center,Boston,États-unis

  • Massachusetts General Hospital,Boston, MA,Stati Uniti

  • Washington University School of Medicine, St. Louis, MO

  • Washington University School of Medicine,St. Louis, MO,Vereinigte Staaten

  • AstraZeneca,Cambridge,Storbritannien

  • AstraZeneca,Cambridge,Royaume-uni

  • Washington University School of Medicine,St. Louis, MO,Vereinigte Staaten

  • Dana-Farber Cancer Institute Boston,Boston,Stati Uniti

  • AstraZeneca,Cambridge,Reino Unido

  • Astra Zeneca, Cambridge, United Kingdom

  • Massachusetts General Hospital, Boston, MA

  • Washington University School of Medicine, St. Louis, MO

  • AstraZeneca,Cambridge,Vereinigtes Königreich

  • Beth Israel Deaconess Medical Center,Boston,États-unis

  • Massachusetts General Hospital,Boston,Vereinigte Staaten

  • AstraZeneca,Cambridge,Соединённое Королевство

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Chronic myelomonocytic leukemia

  • Myelodysplastic Syndrome

  • Thrombocytopenia

  • Neutropenia

Biomarkers

  • Ataxia Telangiectasia And Rad3-Related Protein

  • Paraoxonase 1

  • Hormone receptor

  • Splicing Factor 3b Subunit 1

Drug/Treatment

  • AZD6738

Outcome

  • N/A

Study Design

  • Simon'S Two Stage Design

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved